Format

Send to

Choose Destination
Cancer Chemother Pharmacol. 2001 Dec;48(6):488-92.

Gemcitabine activity in cervical cancer cell lines.

Author information

1
Molecular Biology Laboratory, Basic Research Division, Instituto Nacional de Cancerologia, Mexico City, Mexico.

Abstract

PURPOSE:

Gemcitabine (2',2'-difluorodeoxycytidine) is an antineoplastic agent with activity against a variety of solid tumors. To investigate its in vitro activity toward cervical cancer, we exposed six cervical cancer cell lines to gemcitabine.

METHODS:

Combinational cytotoxic studies using viability tests and clonogenicity assays.

RESULTS:

Gemcitabine was cytostatic and cytotoxic in some of the lines at peak plasma concentrations similar to those achieved in clinical trials. Gemcitabine was also found to effectively synergize with cisplatin and showed a radiosensitizing effect in these cells. The cytotoxicity observed in sensitive cell lines was due to apoptosis, as demonstrated by DNA fragmentation assays.

CONCLUSIONS:

We recommend performing additional in vitro experimentation so that these results can be confirmed to support clinical trials of gemcitabine in cervical cancer patients both as first-line therapy and with concomitant radiation.

PMID:
11800030
DOI:
10.1007/s002800100370
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center